Ambrx Biopharma Stock Price, News & Analysis

AMAM NASDAQ

Company Description

Ambrx Biopharma (NASDAQ: AMAM) is a publicly traded company.

AMAM stock has declined 100.0% over the past year.

This page provides a comprehensive overview of AMAM stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

-100%

Performance 1 year

$0.0

Market Cap

63.4M

Shares outstanding

Ambrx Biopharma (AMAM) stock. Over the past 12 months, the stock has lost 100.0%.

Latest News

View All

October 29, 2024

—

Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

management

March 6, 2024

+0.07%

Ambrx Shareholders Approve Acquisition by Johnson & Johnson

acquisition

January 8, 2024

+101.54%

Ambrx Announces Sale to Johnson & Johnson

January 8, 2024

+101.54%

Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer

acquisition

December 14, 2023

+1.51%

Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)

November 28, 2023

+3.94%

Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

clinical trial

Ambrx Biopharma has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 3 with negative movement. Key topics include management, acquisition, clinical trial, fda approval, conferences. View all AMAM news →

SEC Filings

View All

No SEC filings available for AMAM.

Financial Highlights

View Full Financials

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months